CONCISE REPORT
The genetic contribution to severe post-traumatic osteoarthritis

Ana M Valdes,1,2 Sally A Doherty,1 Kenneth R Muir,3,4 Margaret Wheeler,1 Rose A Maciewicz,5 Weiya Zhang,1 Michael Doherty1

ABSTRACT
Objective to compare the combined role of genetic variants loci associated with risk of knee or hip osteoarthritis (OA) in post-traumatic (PT) and non-traumatic (NT) cases of clinically severe OA leading to total joint replacement.
Methods A total of 1590 controls, 2168 total knee replacement (TKR) cases (33.2% PT) and 1567 total hip replacement (THR) cases (8.7%) from 2 UK cohorts were genotyped for 12 variants previously reported to be reproducibly associated with risk of knee or hip OA. A genetic risk score was generated and the association with PT and NT TKR and THR was assessed adjusting for covariates.
Results For THR, each additional genetic risk variant conferred lower risk among PT cases (OR=1.07, 95% CI 0.96 to 1.19; p=0.24) than NT cases (OR 1.11, 95% CI 1.06 to 1.17; p=1.55×10−5). In contrast, for TKR, each risk variant conferred slightly higher risk among PT cases (OR 1.12, 95% CI 1.07 to 1.19; p=1.82×10−5) than among NT cases (OR 1.08, 95% CI 1.03 to 1.1; p=0.00063).
Conclusions Based on the variants reported to date PT TKR cases have at least as high a genetic contribution as NT cases.

INTRODUCTION
Large joint osteoarthritis (OA) is a common complex disorder with multiple genetic, constitutional and environmental risk factors and marked variability in phenotype.1, 2
OA is divided into ‘primary’ OA, considered to result mainly from genetic and constitutional factors, and ‘secondary’ OA when there is an obvious cause of joint insult.3 A long-recognised risk factor for OA is direct joint injury, such as a subchondral fracture, meniscectomy, anterior cruciate tear or a deforming tibial or femoral fracture that results in poor alignment or leg length shortening.4 5 An estimated 12% of symptomatic OA may be attributed to a post-traumatic (PT) cause6 and differences in radiographic patterns have been reported between primary and PT knee OA cases.7 However, two studies that examined the relationship between hand OA and the risk of developing knee OA following meniscectomy found that the presence of hand OA associated with a higher frequency and radiographic severity of post-meniscectomy OA,8 9 demonstrating that development of OA following a meniscal tear and subsequent surgery are not necessarily of secondary origin.
Genetic factors are known to influence risk of hip OA, knee OA and generalised OA (see Valdes and Spector10). Recent genetic association studies have identified a number of genetic variants associated with knee or hip OA or with severe large joint OA leading to total joint arthroplasty.11–15 To date, 12 independent variants have been reported to be associated with risk of hip or knee OA or related traits with a statistical significance level of p<1×10−7 with (table 1).

PT OA definition
PT THR was defined as THR in the presence of hip injury and PT TKR as TKR in the presence of knee injury as described in the online supplementary methods section.

Laboratory methods
Genomic DNA was extracted from peripheral blood leukocytes of affected individuals and controls using standard protocols. Genotyping was carried out by Kbioscience Ltd, Hertfordshire, UK. Single nucleotide polymorphisms (SNPs) were genotyped using the Kompetitive Allele Specific PCR (KASPar) chemistry.

Statistical analysis
Genetic score
The sum of risk alleles (which can take values 0, 1 or 2 for each variant) as defined in table 1 over all variants was computed for each study participant. Individuals with more than 1 missing genotype for all 12 variants were excluded, otherwise the genotype was imputed using the allele frequency in the population.
Logistic regressions using TKR or THR as outcomes and including age, gender, (BMI) and knee genetic risk score (for TKR) or hip genetic risk score (for THR) were performed. Analyses were
carried out including all TKR (or THR) cases, only PT cases (PT-TKR or PT-THR) and only NT cases (NT-TKR or NT-THR). Results are reported as OR and corresponding 95% CI for the GOAL and Nottingham cohorts separately. ORs were also meta-analysed for both cohorts using a fixed effects analysis. Analyses were performed using R V.2.13.1 (http://www.r-project.org/).

RESULTS

The list of variants investigated in this study is shown in table 1 along with the best-reported p value in the literature. The role of injury as a risk factor was assessed in the GOAL study where history of trauma was recorded for cases and controls. After adjustment for age, sex and BMI the risk estimates found were OR=3.27, (95 % CI 2.51 to 4.25; p<1.1×10−16) for TKR following trauma or in the absence of injury. After adjustment for age, sex and BMI the risk estimates found were OR=5.08 (95 % CI 3.05 to 8.47; p<4.2×10−16) for THR. The combined genetic and descriptive statistics risks in each cohort are shown in table 2. These factors were analysed in each cohort to assess their role in defining risk of THR and TKR following trauma or in the absence of injury.

The mean of each of these risk factors stratified by injury status shows, as expected, a significantly younger age and a higher proportion of men in the post-trauma category (see online supplementary table S1).

The knee genetic risk score for TKR and the hip genetic risk score for THR are both significantly related to risk of total joint replacement (table 3). The average OR contributed by each additional variant carried is similar to those reported in the studies that identified these genetic variants (1.11 for hip OA risk variants and 1.09 for knee OA risk). Age and sex differ contribute differently to risk of PT-TKR and NT-TKR (see online supplementary table S1). We did not observe a significant difference in the risk conferred by knee genetic risk factors, but the OR is slightly higher for PT-TKR cases (OR=1.12) than for non-traumatic cases (OR=1.08). For THR only the gender composition is significantly different between NT and PT cases (see online supplementary table S1). The genetic risk conferred does not achieve statistical significance among PT-TKR cases and is lower (OR=1.07) than among NT-THR cases (OR=1.11) where it is highly significant. Results were also computed excluding individuals with missing genotypes (see online supplementary table S2) and are very similar to those using imputed genotypes for missing data.

DISCUSSION

In this study we report for the first time the role of genetic factors in PT clinically severe OA requiring total joint replacement and compare it to the role that these same genetic factors play among ‘primary’ cases. Our hypothesis was that primary cases would carry a larger number of genetic risk variants than PT OA cases. However, the OR estimates for hip and knee risk scores are not significantly different between PT and NT subjects. Among TKR cases PT cases appear to carry a non-significantly larger proportion of risk variants. Among THR cases a lower contribution of genetic risk factors was seen in PT cases that did not achieve statistical significance.

Table 1 Genetic variants used to generate the genetic risk score

| Gene | SNP | DNA change | Reference | Trait associated | p Value in Caucasians | RAF controls (%) | Risk allele | Hip gene | Knee gene |
|------|-----|------------|-----------|-----------------|-----------------------|------------------|-------------|----------|----------|
| GDF5 | rs143383 | T/C | Valdes et al1 | Knee OA | 8×10−9 | 61.9 | T | – | + |
| COGS* | rs4730250 | A/G | Evandelou et al12 | Knee OA | 9×10−9 | 19.3 | G | – | + |
| MCF2L | rs11842874 | A/G | Day-Williams et al13 | Hip or knee OA | 9.2×10−9 | 91.5 | A | + | + |
| PTHHL* | rs10492367 | A/C | arcOGEN14 | Hip OA | 1.5×10−8 | 21.0 | A | + | – |
| SUPF3H | rs10948172 | G/A | arcOGEN14 | Hip or knee OA in men | 7.9×10−8 | 28.6 | G | + | + |
| TP63 | rs12107036 | A/G | arcOGEN14 | THR in women | 6.7×10−8 | 53.6 | G | – | – |
| FAP* | rs9350591 | C/T | arcOGEN14 | THR | 2.4×10−10 | 10.9 | T | – | + |
| GLN3* | rs11177 | A/G | arcOGEN14 | THR | 7.2×10−11 | 39.0 | A | + | + |
| DOTT1 | rs12982744 | C/G | Castaño-Betancourt et al15 | Minimum joint space width† | 1.1×10−11 | 60.2 | G | + | – |
| ASTN2 | rs4836732 | C/T | arcOGEN14 | THR | 6.1×10−10 | 49.7 | C | + | – |
| FTO | rs8044769 | C/T | arcOGEN14 | THR in women | 6.8×10−8 | 51.3 | C | – | + |
| CHST11 | rs835487 | A/G | arcOGEN14 | THR | 1.6×10−8 | 34.0 | C | + | – |

*For concordance only one of the genes in the region is shown. rs4730250 maps to a cluster of genes that comprises COGS, HBP1, GPR22, PRKAR2B, DUS4L and BCAP29. rs10492367 maps between PTNLH and KLDN3. rs9350591 maps between FAP and SENP6. rs11177 maps to an amino-acid change within GLN3 but is in strong linkage disequilibrium (LD) with variants in the GUBED1 gene.

†Association with hip OA reported is p<1.1×10−9.

Table 2 Descriptive statistics in the two study cohorts

| Factor | Controls | TKR | THR |
|--------|----------|-----|-----|
| GOAL study, n: | 879 | 863 | 938 |
| Nottingham case control, n: | 711 | 1305 | 629 |
| Female, % | 57.0% | 55.2% | 57.9% |
| Age (SD) | 66.29 (8.97) | 69.75 (9.21) | 70.39 (8.75) |
| BMI (SD) | 26.57 (3.93) | 30.15 (5.61) | 28.83 (4.88) |
| Knee gene score (SD) | 6.88 (1.62) | 7.17 (1.68) | 6.90 (1.74) |
| Hip gene score (SD) | 6.14 (1.62) | 6.10 (1.57) | 6.41 (1.69) |
| Hip injury, % | NA | 5.2% | 10.8% |
| Knee injury, % | NA | 33.6% | 17.0% |
| BMI, body mass index; GOAL, Genetics of Osteoarthritis and Lifestyle; NA, not applicable; THR, total hip replacement; TKR, total knee replacement.
Our data indicate that among the risk factors to take into account in PT knee OA cases due to the type of injury experienced. Nevertheless, using the current definitions we found strong significant differences in age and gender between PT OA and NT cases, as reported in other studies. Moreover, the questionnaire identified a very high risk due to injury for TKR (OR = 3.27) and THR (OR = 5.08) in the case control design. Such risks are much higher than all genetic factors combined. Thus, in spite of the caveats, the population classified as PT based on questionnaire data appears enriched for true PT OA cases. Another limitation is that the results apply to UK populations and may not generalise to other ethnic groups, but the genetic variants used are only those reported in Caucasians as having a role in risk of OA.

In conclusion, PT hip OA cases appear to have a lower genetic risk load than NT cases, whereas PT knee OA cases have at least as high a genetic contribution as NT cases. These data support the perspective of OA as common complex condition and further challenge a clear separation between ‘primary’ and ‘secondary’ forms of OA.

**Contributors** All authors contributed to the study design, data interpretation and the final manuscript. In addition, AMV analysed and interpreted the data and prepared manuscript. SAD and MD evaluated study subjects. AMV and MD supervised the study.

**Funding** Supported by EC-FP7 programme grant 200800 TREAT-OA and 277849 EURHEALTHAgeing. AstraZeneca UK funded the GOAL study sample and data collection.

**Competing interests** RAM is an employee of AstraZeneca plc.

**Ethics approval** The research ethics committees of Nottingham City Hospital and North Nottinghamshire.

**Provenance and peer review** Not commissioned; externally peer reviewed.

---

**Table 3 Age, sex, BMI and genetic risk scores as risk factors for post-traumatic (PT) and non-traumatic (NT) total joint replacement in two study cohorts**

| Risk factor | Study cohort   | All            | p Value  | PT            | p Value  | NT            | p Value  |
|-------------|----------------|----------------|----------|---------------|----------|---------------|----------|
| **TKR:**    |                |                |          |               |          |               |          |
| Age         | GOAL           | 1.13 (1.12 to 1.15) | 1.10 (1.08 to 1.12) | 1.16 (1.13 to 1.18) |
|             | Nottingham     | 1.07 (1.06 to 1.08) | 1.04 (1.02 to 1.05) | 1.09 (1.07 to 1.11) |
| Sex         | GOAL           | 0.99 (0.78 to 1.24) | 1.06 (1.05 to 1.07) | 5.17E-20 | 1.11 (1.10 to 1.12) | 7.05E-75 |
|             | Nottingham     | 0.76 (0.62 to 0.93) | 0.61 (0.45 to 0.84) | 1.41 (1.08 to 1.83) |
| BMI         | GOAL           | 1.24 (1.21 to 1.27) | 1.20 (1.16 to 1.25) | 1.26 (1.22 to 1.29) |
|             | Nottingham     | 1.21 (1.18 to 1.24) | 1.20 (1.16 to 1.23) | 1.22 (1.19 to 1.25) |
| Knee OA     | GOAL           | 1.08 (1.01 to 1.16) | 1.14 (1.06 to 1.23) | 1.07 (1.01 to 1.14) |
| Risk        | Nottingham     | 1.09 (1.03 to 1.16) | 1.10 (1.02 to 1.12) | 1.10 (1.03 to 1.17) |
| Genes       | Summary        | 1.09 (1.04 to 1.14) | 1.12 (1.07 to 1.19)* | 1.82E-05 | 1.08 (1.03 to 1.13)* | 0.00063 |

| **THR:**    |                |                |          |               |          |               |          |
| Age         | GOAL           | 1.1 (1.08 to 1.11) | 1.06 (1.03 to 1.09) | 1.10 (1.08 to 1.11) |
|             | Nottingham     | 1.07 (1.05 to 1.08) | 1.08 (1.05 to 1.11) | 1.06 (1.05 to 1.08) |
| Sex         | GOAL           | 1.38 (1.13 to 1.69) | 1.04 (0.62 to 1.75) | 1.45 (1.18 to 1.78) |
|             | Nottingham     | 1.03 (0.82 to 1.3) | 1.33 (0.78 to 2.26) | 0.99 (0.78 to 1.26) |
| BMI         | GOAL           | 1.11 (1.09 to 1.14) | 1.31 (1.08 to 1.19) | 1.11 (1.09 to 1.14) |
|             | Nottingham     | 1.15 (1.12 to 1.18) | 1.15 (1.08 to 1.22) | 1.15 (1.12 to 1.19) |
| Hip OA      | GOAL           | 1.13 (1.11 to 1.15) | 2.78E-42 | 1.14 (1.11 to 1.18) | 2.78E-42 | 1.13 (1.11 to 1.15) | 4.83E-40 |
| Risk        | Nottingham     | 1.08 (1.01 to 1.16) | 1.08 (0.92 to 1.27) | 1.08 (1.01 to 1.16) |
| Genes       | Summary        | 1.11 (1.06 to 1.16) | 1.2E-05 | 1.07 (0.96 to 1.19)* | 0.24 | 1.11 (1.06 to 1.17)* | 1.55E-05 |

*The difference between the PT and NT ORs did not reach statistical significance (p>0.05) for TKR and THR.

BMI, body mass index; GOAL, Genetics of Osteoarthritis and Lifestyle; OA, osteoarthritis; THR, total hip replacement; TKR, total knee replacement.
REFERENCES

1. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747–57.

2. Dieppe PA, Lohmander LS. Pathogenesis and management of pain in osteoarthritis. Lancet 2005;365:965–73.

3. Herrero-Beaumont G, Roman-Blas JA, Castañeda S, et al. Primary osteoarthritis no longer primary: three subsets with distinct etiological, clinical, and therapeutic characteristics. Semin Arthritis Rheum 2009;39:71–80.

4. Anderson DD, Chubinskaya S, Guilak F, et al. Post-traumatic osteoarthritis: improved understanding and opportunities for early intervention. J Orthop Res 2011;29:802–9.

5. Muthuri SG, McWilliams DF, Doherty M, et al. History of knee injuries and knee osteoarthritis: a meta-analysis of observational studies. Osteoarthritis Cartilage 2011;19:1286–93.

6. Brown TD, Johnston RC, Saltzman CL, et al. Post-traumatic osteoarthritis: a first estimate of incidence, prevalence, and burden of disease. J Orthop Trauma 2006;20:739–44.

7. Sward P, Kostogiannis I, Neuman P, et al. Differences in the radiological characteristics between post-traumatic and non-traumatic knee osteoarthritis. Scand J Med Sci Sports 2010;20:731–9.

8. Doherty M, Watt I, Dieppe P. Influence of primary generalised osteoarthritis on development of secondary osteoarthritis. Lancet 1983;2:8–11.

9. Englund M, Paradowski PT, Lohmander LS. Association of radiographic hand osteoarthritis with radiographic knee osteoarthritis following meniscectomy. Arthritis Rheum 2004;50:469–75.

10. Valdes AM, Spector TD. The contribution of genes to osteoarthritis. Rheum Dis Clin North Am 2008;34:581–603.

11. Valdes AM, Evangelou E, Kerkhof HJ, et al. The GDF5 rs143383 polymorphism is associated with osteoarthritis of the knee with genome-wide statistical significance. Ann Rheum Dis 2011;70:873–5.

12. Evangelou E, Valdes AM, Kerkhof HJ, et al. Meta-analysis of genome-wide association studies confirms a susceptibility locus for knee osteoarthritis on chromosome 7q22. Ann Rheum Dis 2011;70:349–55.

13. Day-Williams AG, Southam L, Panoutsopoulou K, et al. A variant in MCF2L is associated with osteoarthritis. Am J Hum Genet 2011;89:446–50.

14. arcOGEN Consortium and arcOGEN Collaborators. Identification of new susceptibility loci for osteoarthritis—the arcOGEN study. Lancet 2012;380:815–23.

15. Castaño-Betancourt MC, Cailotto F, Kerkhof HJ, et al. Genome-wide association and functional studies identify the DOT1L gene to be involved in cartilage thickness and hip osteoarthritis. Proc Natl Acad Sci USA 2012;109:8218–23.